Brokerages Set Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Target Price at $109.00

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) has been given an average recommendation of “Hold” by the fifteen ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating and two have issued a buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $109.00.

Several research firms have weighed in on VRNA. Cantor Fitzgerald reiterated an “overweight” rating and issued a $100.00 price objective on shares of Verona Pharma PLC American Depositary Share in a research note on Wednesday, October 8th. HC Wainwright reiterated a “neutral” rating and issued a $107.00 price objective (up previously from $90.00) on shares of Verona Pharma PLC American Depositary Share in a research note on Monday, July 14th. Wolfe Research lowered shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 10th. Piper Sandler lowered shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 10th. Finally, Roth Capital lowered shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 10th.

Verona Pharma PLC American Depositary Share Stock Performance

Shares of VRNA stock opened at $106.91 on Monday. Verona Pharma PLC American Depositary Share has a 1-year low of $31.09 and a 1-year high of $106.93. The company has a current ratio of 10.71, a quick ratio of 10.54 and a debt-to-equity ratio of 0.87. The company has a market capitalization of $9.21 billion, a price-to-earnings ratio of -107.99 and a beta of 0.05. The stock’s fifty day simple moving average is $106.18 and its 200-day simple moving average is $89.97.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.14. Verona Pharma PLC American Depositary Share had a negative return on equity of 21.12% and a negative net margin of 36.62%.The business had revenue of $103.14 million for the quarter, compared to the consensus estimate of $90.41 million. On average, sell-side analysts predict that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current fiscal year.

Insider Transactions at Verona Pharma PLC American Depositary Share

In other news, Director Martin Edwards sold 10,808 shares of the stock in a transaction on Friday, August 1st. The shares were sold at an average price of $13.14, for a total transaction of $142,017.12. Following the transaction, the director owned 157,992 shares in the company, valued at $2,076,014.88. This represents a 6.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Michael Austwick sold 11,288 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $13.14, for a total transaction of $148,324.32. Following the transaction, the director owned 12,712 shares in the company, valued at approximately $167,035.68. This trade represents a 47.03% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 540,584 shares of company stock worth $7,103,274. 4.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. GAMMA Investing LLC increased its stake in shares of Verona Pharma PLC American Depositary Share by 5.6% during the 2nd quarter. GAMMA Investing LLC now owns 1,940 shares of the company’s stock worth $183,000 after purchasing an additional 103 shares during the last quarter. Geneos Wealth Management Inc. increased its stake in shares of Verona Pharma PLC American Depositary Share by 44.2% during the 1st quarter. Geneos Wealth Management Inc. now owns 630 shares of the company’s stock worth $40,000 after purchasing an additional 193 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Verona Pharma PLC American Depositary Share by 4.6% during the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,675 shares of the company’s stock worth $442,000 after purchasing an additional 205 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Verona Pharma PLC American Depositary Share by 3.4% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,880 shares of the company’s stock worth $1,124,000 after purchasing an additional 394 shares during the last quarter. Finally, Personal CFO Solutions LLC increased its stake in shares of Verona Pharma PLC American Depositary Share by 7.2% during the 2nd quarter. Personal CFO Solutions LLC now owns 6,495 shares of the company’s stock worth $614,000 after purchasing an additional 439 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.